Publicaciones en colaboración con investigadores/as de Hospital Universitario Reina Sofia (10)

2024

  1. Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)

    Clinical and Translational Oncology

2023

  1. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2647-2664

2021

  1. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

  2. The role of CDK4/6 inhibitors in early breast cancer

    Breast, Vol. 58, pp. 160-169

2020

  1. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428

2019

  1. Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept

    Clinical Drug Investigation, Vol. 39, Núm. 7, pp. 595-606

  2. Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer

    European Journal of Cancer Care, Vol. 28, Núm. 6

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2014

  1. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

    Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 160-166